Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Amgen (AMGN) reported positive topline Phase 3 results from the OASIZ 301 study of dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.
The trial met its primary endpoint, showing statistically significant and clinically meaningful improvement in systemic disease activity at Week 48, measured by the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). Improvements in ESSDAI were seen as early as Week 4 and were sustained through Week 48. The most common adverse events (≥5% and more frequent than placebo) were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions, generally mild to moderate, with low and balanced discontinuation rates. No imbalance in thromboembolic events or opportunistic infections was observed. Amgen plans to present detailed data at an upcoming medical meeting and expects the Phase 3 OASIZ 303 study to complete in Q4 2026.
Amgen (AMGN) received U.S. FDA approval on Sept. 14, 2026 to update IMDELLTRA (tarlatamab-dlle) prescribing information, sharply reducing recommended monitoring time for the first two treatment doses in an appropriate healthcare setting.
Patients with extensive-stage small cell lung cancer (ES‑SCLC) receiving IMDELLTRA should now be monitored for 6–8 hours from the start of the first two infusions, down from the previously recommended 22–24 hours, followed by a next‑day assessment including vital signs. The label update is limited to these initial doses; later‑cycle monitoring remains at 6–8 hours for the third dose and Cycle 2, 3–4 hours for Cycles 3–4, and 2 hours from Cycle 5 onward. Patients are advised to remain within one hour of appropriate care for 48 hours after Cycle 1 Day 1 and Day 8 doses.
Amgen (AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Executive vice president Jay Bradner and executive vice president and chief financial officer Thomas Dittrich will speak at the event. A live webcast will be available to media, investors and the public via the Investors section of Amgen's website and will be archived for replay for at least 90 days.
Amgen (AMGN) reported that the Phase 3 DeLLphi-305 trial met its primary endpoint, showing a statistically significant and clinically meaningful overall survival improvement for IMDELLTRA (tarlatamab-dlle) plus Imfinzi (durvalumab) versus durvalumab alone in first-line maintenance treatment of extensive stage small cell lung cancer (ES-SCLC).
The combination also achieved statistically significant and clinically meaningful gains in progression-free survival and objective response rate. Safety of IMDELLTRA with durvalumab was consistent with the known profiles of the individual drugs, with no new or unexpected safety signals, and required monitored infusions on Cycle 1 Day 1 and Day 8. DeLLphi-305 randomized 563 patients 1:1 and is the first Phase 3 study including a Bispecific T-cell Engager (BiTE) therapy to show an overall survival benefit in first-line maintenance ES-SCLC. Amgen plans detailed data presentation and regulatory discussions.
Amgen (AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026. Executive vice president and CFO Thomas Dittrich, CMO Paul Burton and SVP Global Marketing and Access Kave Niksefat are scheduled to speak.
The presentation will be webcast live on Amgen’s website under the Investors section and listed on the Investor Relations Events Calendar. The webcast will be open to media, investors and the public, and will remain archived and available for replay for at least 90 days after the event.
Amgen (NASDAQ: AMGN) reported new Phase 3 VESALIUS-CV data showing Repatha (evolocumab) reduced the risk of death by 20% in more than 12,000 high-risk adults without prior heart attack or stroke, when added to statins or other LDL-C–lowering therapy, over a median 4.6-year follow-up.
Repatha lowered overall and cardiovascular mortality, reduced first, subsequent and total cardiovascular events, and cut heart attack risk as early as six months. Prior VESALIUS-CV results showed a 25% relative reduction in 3-point MACE, 19% in 4-point MACE, 36% fewer heart attacks, and median LDL-C of 45 vs 109 mg/dL.
Amgen (NASDAQ:AMGN) and AstraZeneca reported positive top-line Phase 3 results from the randomized, double-blind CROSSING trial of TEZSPIRE (tezepelumab-ekko) in 368 patients aged 12–80 years with symptomatic, histologically active eosinophilic esophagitis (EoE). TEZSPIRE, given subcutaneously every four weeks at two dose levels versus placebo, achieved statistically significant and clinically meaningful improvements in both co-primary endpoints at week 24: histologic remission (low peak eosinophil counts in esophageal tissue) and reduction in frequency and severity of dysphagia measured by the Dysphagia Symptom Questionnaire. According to Amgen, these benefits, along with key secondary endpoints including endoscopic and histologic measures, were sustained through week 52, and the safety profile was generally consistent with TEZSPIRE’s approved indications in severe asthma and chronic rhinosinusitis with nasal polyps.
Amgen (NASDAQ: AMGN) reported second-quarter 2026 total revenues of $10.1 billion, up 10% year over year, with total product sales up 9% to $9.54 billion, driven by volume growth and 22 products delivering double-digit sales increases. Six key growth drivers grew 26% and generated nearly 70% of product sales.
GAAP EPS rose 65% to $4.37, GAAP operating income increased to $3.5 billion, and GAAP operating margin expanded 6.5 points to 36.8%. Non-GAAP EPS increased 4% to $6.29, while non-GAAP operating margin edged down to 48.4%. Free cash flow was $3.5 billion versus $1.9 billion a year earlier. The company paid a quarterly dividend of $2.52 per share, up 6% year over year, ended the quarter with $14.0 billion in cash and $57.3 billion of debt, and guided 2026 revenues to $38.2–$39.4 billion and non-GAAP EPS to $22.30–$23.50.
Amgen (NASDAQ:AMGN) announced that its Board of Directors has declared a $2.52 per share cash dividend for the third quarter of 2026. The dividend is scheduled to be paid on September 11, 2026 to stockholders of record as of the close of business on August 21, 2026.
Amgen (NASDAQ:AMGN) will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of U.S. financial markets, followed by an investor conference call at 4:30 p.m. ET with CEO Robert A. Bradway and senior management.
A live audio webcast, along with other selected management presentations, will be accessible via the Investors section of Amgen's website and listed on the Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days.